Amicus Therapeutics (FOLD) Misses Q3 EPS by 10c

Amicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of ($0.41), $0.10 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $10.9 million versus the consensus estimate of $9.52 million.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Hyperscale Data signs $1.2B AI compute deal for Michigan campus
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance